Immunomedics Inc. (NASDAQ:IMMU) shares fell 4% on Thursday . The company traded as low as $2.66 and last traded at $2.66, with a volume of 350,614 shares traded. The stock had previously closed at $2.77.

A number of research firms have weighed in on IMMU. Wells Fargo & Co. lowered shares of Immunomedics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, June 21st. Jefferies Group reissued a “buy” rating and set a $5.00 target price on shares of Immunomedics in a research report on Monday, June 6th. Finally, Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “sell” rating in a research report on Tuesday, May 10th.

The company’s 50-day moving average price is $2.74 and its 200 day moving average price is $2.92. The company’s market capitalization is $262.67 million.

Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.06. On average, equities research analysts forecast that Immunomedics Inc. will post ($0.47) EPS for the current fiscal year.

In other news, CEO Cynthia L. Goldenberg sold 63,959 shares of the stock in a transaction on Monday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $261,592.31. Following the completion of the sale, the chief executive officer now owns 703,029 shares of the company’s stock, valued at $2,875,388.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Don C. Stark sold 9,900 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $2.97, for a total transaction of $29,403.00. Following the sale, the director now directly owns 55,848 shares of the company’s stock, valued at approximately $165,868.56. The disclosure for this sale can be found here.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.